GILD Share Price

Open 71.25 Change Price %
High 71.76 1 Day 0.72 1.02
Low 70.72 1 Week 5.65 8.61
Close 71.24 1 Month 6.74 10.45
Volume 14019850 1 Year -7.01 -8.96
52 Week High 88.85
52 Week Low 63.76
GILD Important Levels
Resistance 2 72.20
Resistance 1 71.81
Pivot 71.24
Support 1 70.67
Support 2 70.28
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
DCTH 0.22 37.50%
FNFG 10.18 -0.20%
AVEO 1.95 56.00%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
More..
NASDAQ USA Top Gainers Stocks
AVEO 1.95 56.00%
LOCM 0.09 50.00%
DCTH 0.22 37.50%
WRES 0.09 28.57%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
OPXAW 0.15 25.00%
PTSX 0.15 25.00%
FRED 12.61 23.02%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
SPIR 0.01 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
More..

Gilead Sciences, Inc. (NASDAQ: GILD)

GILD Technical Analysis 2
As on 26th Jun 2017 GILD Share Price closed @ 71.24 and we RECOMMEND Sell for LONG-TERM with Stoploss of 72.36 & Strong Buy for SHORT-TERM with Stoploss of 66.20 we also expect STOCK to react on Following IMPORTANT LEVELS.
GILD Target for June
1st Target up-side 67.77
2nd Target up-side 69.78
3rd Target up-side 71.8
1st Target down-side 62.01
2nd Target down-side 60
3rd Target down-side 57.98
GILD Other Details
Segment EQ
Market Capital 51045679104.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.gilead.com
GILD Address
GILD
333 Lakeside Drive
Foster City, CA 94404
United States
Phone: 650-574-3000
Fax: 650-578-9264
GILD Latest News
Interactive Technical Analysis Chart Gilead Sciences, Inc. ( GILD NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Gilead Sciences, Inc.
GILD Business Profile
Gilead Sciences, Inc. (Gilead) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines. Gilead�s primary areas of focus include human immunodeficiency virus (HIV)/AIDS, liver diseases, such as hepatitis B and C and cardiovascular/metabolic and respiratory conditions. The Company has operations in North America, Europe and Asia Pacific. The Company�s products include Atripla, Truvada, Viread, Complera/Eviplera, Emtriva, Hepsera, Letairis, Ranexa, Lexiscan/Rapiscan, AmBisome, Vistide, Macugen, Cayston and Tamiflu. In January 2012, the Company acquired Pharmasset, Inc. On February 8, 2013, its subsidiary, acquired YM BioSciences Inc.